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Abstract There is a dearth of evidence on injection drug
use and associated HIV infections in Kenya. To generate
population-based estimates of characteristics and HIV/STI
prevalence among people who inject drugs (PWID) in
Nairobi, a cross-sectional study was conducted with 269
PWID using respondent-driven sampling. PWID were
predominantly male (92.5 %). An estimated 67.3 %
engaged in at least one risky injection practice in a typical
month. HIV prevalence was 18.7 % (95 % CI 12.3–26.7),
while STI prevalence was lower [syphilis: 1.7 % (95 % CI
0.2–6.0); gonorrhea: 1.5 % (95 % CI 0.1–4.9); and Chla-
mydia: 4.2 % (95 % CI 1.2–7.8)]. HIV infection was
associated with being female (aOR, 3.5; p = 0.048), hav-
ing first injected drugs 5 or more years ago (aOR, 4.3;
p = 0.002), and ever having practiced receptive syringe
sharing (aOR, 6.2; p = 0.001). Comprehensive harm
reduction programs tailored toward PWID and their sex
partners must be fully implemented as part of Kenya’s
national HIV prevention strategy.
Keywords HIV prevalence  STI prevalence  People
who inject drugs  Kenya  Integrated biobehavioral 
Surveillance survey  Respondent-driven sampling
Background
Injection drug behaviors have been recognized as key
facilitators of HIV transmission since the beginning of the
epidemic [1–3]. In 2010, there were an estimated 15.9
million (ranging from 11 to 21.2 million) people who
injected drugs (PWID) globally, with one in five estimated
to be HIV-positive [2]. While Southeast and East Asia have
the largest number of PWID [4], recent evidence shows an
increase in injection drug use and associated HIV infec-
tions in sub-Saharan Africa, where the burden of HIV is
already the highest in the world [5–16]. Despite a lack of
comprehensive evidence, it is clear that PWID in sub-
Saharan Africa are at great risk for acquiring and
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transmitting HIV in the context of few prevention
interventions targeted toward this population and lack
of capacity to handle key populations at risk for HIV
such as men who have sex with men, sex workers, and
PWID, in the current state of the burdened healthcare
system.
African countries with significant HIV epidemics such
as Kenya, where general population prevalence is 5.6 %
[17], are only now in the beginning stages of understanding
the role of key populations with higher risk for exposure to
HIV infection in their epidemic, including PWID. In
Kenya, use of injected heroin reportedly increased in the
late 1990s with the availability of ‘white crest’ from
Thailand [18]. While white crest replaced ‘brown sugar’, a
lower grade of heroin, user habits shifted from inhalation of
the vapor to injecting [18]. The number of PWID has been
a point of contention among researchers, however, the
consensus is now estimated to be 6,216–10,937 in Nairobi
and 3,718–8,500 in the Coastal Kenya [19–21]. The
national size of the PWID population in Kenya, however,
has only been estimated to be 30,000 [22] to 35,000 [4]
PWID. Although the population of PWID in Kenya is
relatively small, HIV transmission through injection yields
a markedly higher HIV incidence rate compared to trans-
mission through heterosexual sex [6]; PWID have two
times as high a probability of HIV transmission per risky
exposure compared to exposure from casual heterosexual
sex [23]. Thus while only an estimated 5.8 % of new HIV
infections in Nairobi and 6.1 % on the coast are attributed
to PWID, there is great potential for the HIV epidemic to
rapidly gain traction in this population [6]. At the time of
this study, there were no systematic harm reduction pro-
grams for PWID in Kenya. Based on our formative
assessment for this study, in Nairobi, PWID typically
obtained needles and syringe from pharmacists for about
KSH 15–20 (about USD 0.16–0.22). The formative
assessment also revealed that PWID face a great deal of
stigma from the community as their behavior is criminal-
ized and the community associates drug users with criminal
activity since many engage in stealing as a means to sup-
port their drug habit. The police often use injection track
marks on the body as a basis for arrests. PWID may also be
arrested for being in possession of any drug injection
paraphernalia.
While limited data exist on characteristics of PWID in
Kenya, studies in other countries show PWID commonly
engage in high-risk injection behaviors, such as sharing
previously used equipment (e.g., needles) [24–27] and also
engage in high-risk sexual practices, including exchanging
sex for money or drugs [28–34]. Migratory and high-risk
sexual behaviors of PWID can act as a bridge to the general
population as well [34]. HIV prevalence estimates in
Kenya are also limited, but point to highly concentrated
pockets of HIV infection within these communities. Pre-
vious reports of HIV prevalence in Kenyan PWID range
from 31 to 50 % in Nairobi and coastal areas [35–37];
however, these studies relied on convenience sampling or
service records, making inferences to the overall PWID
population difficult.
This is the first study implemented to provide popula-
tion-based estimates of characteristics of PWID and the
prevalence of HIV and STI in this high-risk population in
Nairobi. This information is crucial for guiding HIV pre-
vention programs in Nairobi.
Methods
Study Population and Sampling
Between January and March 2011, PWID were recruited
for a cross-sectional study using respondent-driven sam-
pling (RDS), an adaptive peer-recruitment sampling
method [38–41]. A sample recruited using RDS which
meets the underlying assumptions can be used to estimate
population parameters. Recruitment was initiated with six
‘seeds’ (initial participants) who were purposively selected
in consultation with key informants in the PWID commu-
nity and diversified on characteristics including sex, age,
education, and place where they buy drugs or inject. Seeds
were given two recruitment coupons to recruit peers. This
process was repeated with subsequent recruits until the
research team determined that recruitment was stalling and
that only a few PWID could be recruited beyond that point.
The number of peers that participants could recruit was
limited to keep the number of daily PWID arriving at the
study site at a manageable level, encourage long recruit-
ment chains to yield a wider cross-section of the
population.
Eligible participants were males and females 18 years
and older who reported injecting illicit drugs in the previ-
ous 3 months, lived in Nairobi or adjacent urban areas, and
were willing to provide written informed consent. Study
activities were conducted at the National AIDS and STI
Control Programme (NASCOP) voluntary counseling and
testing (VCT) center located within the Kenyatta National
Hospital compound in Nairobi.
Survey Data Collection
Face-to-face interviews were conducted in private by
trained nurse counselors who used handheld computers.
Survey questions included demographics, HIV knowl-
edge, sexual risk and prevention behaviors, drug use, HIV
testing history, and experience with violence and
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discrimination. Upon completion of the behavioral inter-
view, HIV counseling and testing was offered to partici-
pants who elected to be tested. An RDS coupon manager
software was used to track recruitment and compensation.
Participants were compensated KES 400 (approximately
USD 4.25) for participating. Participants also received
KES 200 (approximately USD 2.15) for each peer they
recruited into the study, in addition to KES 200 for
transport. Biometric software was used to identify dupli-
cate recruits, confirm correct ownership of a recruit’s
coupon, and identify recruits during follow-up. The soft-
ware creates a unique ID number based on the scan of the
participant’s fingerprint, which is immediately deleted
after the unique ID is created.
Laboratory Procedures
Per national guidelines [42], HIV testing was conducted
using a parallel algorithm with Determine and Unigold
rapid tests (Determine; Abbott Laboratories, Abbott Park,
Illinois, USA; Unigold; Trinity Biotech plc, Bray, Ire-
land), and Bioline (Standard Diagnostics Inc., Gyeonggi-
Do, South Korea) as a tiebreaker for discordant results.
Those who tested positive were referred to government
clinics and some NGO clinics (e.g., NOSET) for further
management. For syphilis, rapid plasma reagent (RPR)
assays was used for screening, and Treponema palladium
hemagglutination assay (TPHA) test (Human Diagonistic
Worldwide; Wiesbaden, Germany) was used for all
positive RPR tests for confirmation. The rapid C. tra-
chomatis PCR (Roche Amplicor CT/NG test assay, Roche
Molecular Diagnostics; Pleasanton, CA) was used for the
detection of antigens in urine (men) or vaginal (women)
swabs for chlamydia (CT) and gonorrhea (NG). For
female respondents only, detection of T. vaginalis was
performed using the InPouchTM system (BioMed Diag-
nostics, San Jose, California). A vaginal culture was
evaluated for bacterial vaginosis and candidiasis using
Nugent’s scoring criteria, and the KOH test for candidi-
asis. For quality assurance of HIV testing, additional HIV
testing was conducted off-site. The rapid testing algorithm
was repeated at the University of Nairobi Institute of
Tropical and Infectious Diseases (UNITID) laboratory for
all HIV-positive results and for 5 % of HIV-negative
results. PCR was used to resolve any discrepancies.
Samples for all STIs were sent and processed at UNITID
laboratory. For NG and CT, quality control panels were
provided by the Institute of Tropical Medicine (ITM). A
panel was tested prior to study implementation and every
4 months after; results were immediately reported to the
ITM. For quality control of syphilis, all RPR positive
specimens and 5 % of negative specimens were retested
with TPHA.
Data Analysis
RDS Analysis Tool (RDSAT) software version 6.0 was
used to produce point estimates and 95 % confidence
intervals (CI) [43]. RDSAT adjusts for recruitment pat-
terns and the relative sizes of participants’ networks and
theoretically produces unbiased estimates of population
characteristics of interest. Multivariable analysis was
conducted to determine factors associated with the pri-
mary outcome of HIV serostatus. The individualized
weights on HIV serostatus were generated in RDSAT,
exported to STATA software (Version 11.0, STATA
Corp., College Station, TX, USA), and used in the logistic
regression analyses with the pweight option. We assessed
collinearity between injection variables related to the last
1 month and lifetime and found no significant collinear-
ity. Variables associated with HIV infection at p \ 0.10
level in the bivariate analysis were included in the initial
multivariable model. Variables not significant at the 0.05
level were systematically removed from the model using
the backwards stepwise method. The final model includes
variables that were associated with HIV infection at
p \ 0.05 level or were considered to be salient con-
founders, such as age.
Variable Definitions
Poly-drug use was defined as concurrent drug use (injected
or non-injected) with at least one other drug injected in the
past 1 month. Sharing drug injection equipment includes
sharing of dropper, water, bleach, and other cleaning
agents. The variable ‘‘risky injection practices’’ is a com-
posite variable that includes using needles/syringe after
someone else used it (referred to hereon as ‘‘receptive
syringe sharing’’), using a pre-filled needle/syringe, front-
or back-loading injections (a method of sharing drugs by
transferring contents from one syringe to another), sharing
of preparation water, sharing of other injections equipment,
or drawing drugs from a common container. A regular
partner was defined as someone with whom the respondent
had an ongoing or long-term intimate sexual relationship; it
included live-in partners and spouses. A casual partner was
defined as a partner with whom the respondent did not have
an ongoing or intimate sexual relationship, and includes
one-time encounters. Commercial partners were those who
the respondent paid for sex or paid the respondent for sex
with money, goods or services.
Ethical Approval
The study protocol was approved by the Kenyatta National
Hospital Ethics and Research Committee, the Population
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Council Institutional Review Board, and the Global AIDS
Program at the Centers for Disease Control and Prevention
(CDC).
Results
Of the 352 PWID screened for eligibility between January
and March 2011, six were seed participants and 77 were
found to be ineligible, yielding an analytic sample of 269
non-seed participants who completed the survey and test-
ing. Figure 1 illustrates the network recruitment chains.
Demographic characteristics and risk behaviors are pre-
sented in Table 1. The median age of PWID was 31 years.
In adjusted analysis, the majority were male (92.5 %),
16.9 % were currently married and 58.6 % were previously
married. PWID mainly earned money through informal or
irregular employment, with only 11.4 % of the population
having formal employment. Nearly one out of five
(18.8 %) earned income through illegal activities and/or
sex work.
Drug Injection Behaviors
Table 2 presents drug using and sexual risk indicators.
While PWID initiated drug use at a median age of
18 years, the median age at first drug injection use was
33 years. The most commonly drug first used in this pop-
ulation of PWID was marijuana (57.2 %) and first drug
injected was white heroin (84.3 %), which is the drug most
commonly injected at the time of the study (by 96.5 % of
participants). Over 40 % of PWID in Nairobi were recent
initiators of injection drug use; an estimated 21.3 % started
injecting 5 or more years ago.
Recent poly-drug use was common with almost two-
thirds using marijuana and 50.1 % using tranquilizers in
addition to heroin in the most recent month. The majority
(77.3 %) injected daily. PWID most commonly injected
Fig. 1 Network diagram of PWID recruitment chain referral in
Nairobi, 2011 (N = 275), by HIV serostatus and lifetime sharing of
needle or syringe. Larger shapes depict seed participants (n = 6);
smaller shapes are recruited respondents (n = 269). Gray HIV-
seronegative respondents (n = 212; 1 seeds). Black HIV-seropositive
respondents (n = 57; 5 seeds). Square Ever receptive syringe sharing
(n = 151; 4 seeds). Circle Never receptive syringe sharing (n = 118;
2 seeds)
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where they buy drugs (60.6 %) or in the street or parks
(32.6 %); 24.9 % injected at home.
PWID engaged in various high-risk injection practices
in the most recent month including receptive syringe
sharing (47.4 %), pre-filled needles and syringes (33.2 %),
front- or back-loading (46.3 %), sharing preparation water
(57.1 %), sharing equipment (56.9 %), and drawing drugs
from a common container (37.9 %). Overall, an estimated
67.3 % engaged in at least one of these risky injection
practices in a typical month, and 80.0 % are estimated to
have ever engaged in any of these practices in their life-
time. An estimated one-half lent their needles or syringe to
someone else in the most recent month. Of these
(n = 141), 23.7 % were HIV-positive and 16.7 % knew
that they were HIV-positive. (Data not shown)
Sexual Risk Behaviors
While over one-half (59.0 %) did not have any sex partners
in the past month, 29.5 % had a regular sex partner (Table 2).
Table 1 Crude and RDS-weighted demographic characteristics of





Age (median 31, IQR 27–37)
18–24 10.0 (27) 9.9 (5.2–15.6)
25–29 26.0 (70) 23.7 (17.0–30.0)
30–34 27.9 (75) 20.2 (22.1–38.9)
35 years or older 36.1 (97) 36.2 (28.9–44.5)
Gender
Male 92.2 (248) 92.5 (86.4–97.5)
Female 7.8 (21) 7.5 (2.5–13.6)
Education
None/incomplete primary 47.6 (128) 51.2 (42.5–59.9)
Completed primary 17.8 (48) 17.2 (11.6–23.3)
Some secondary or higher 34.6 (93) 31.5 (24.0–39.4)
Current marital status
Single, never been married 27.5 (74) 24.4 (17.1–32.0)
Single, formerly married 54.3 (146) 58.6 (50.6–66.5)
Currently married 18.2 (49) 16.9 (11.3–23.9)
Kenyan
Kenyan 98.5 (265) 97.9 (94.9–100)
Non-Kenyan 1.5 (4) 2.1 (0–5.1)
Employment
No income/not employed 4.46 (12) 3.2 (1.4–5.9)
Skilled labor/sales/professional 11.5 (31) 11.4 (6.0–17.0)
Casual laborer/scavenger 34.9 (94) 31.4 (23.7–37.7)
Transport worker 23.1 (62) 22.3 (16.0–31.4)
Illegal activity/sex work 17.1 (46) 18.8 (12.1–26.6)
Other 8.9 (24) 12.8 (7.2–19.3)
Table 2 Crude and RDS-weighted behavioral and HIV prevalence





Median age at first drug use [IQR] 18 [13–20]
Time since first illicit drug use
\10 years 30.7 (82) 30.6 (22.9–38.7)
10–\20 years 49.4 (132) 53.2 (44.4–61.8)
20 years or more 19.9 (53) 16.2 (11.1–22.1)
First illicit drug used
Marijuana 62.1 (167) 57.2 (48.5–66.9)
Heroin 20.8 (56) 22.5 (14.9–29.9)
Other 17.1 (46) 20.3 (14.9–29.9)
Median age at first injection
[IQR]
33 [30–35]
First illicit drug injected
White heroin 84.4 (227) 84.3 (79.2–89.9)
Brown heroin 14.9 (40) 15.5 (9.9–20.6)
Other 0.7 (2) 0.2 (0.1–0.5)
Time since first injection
B6 months 35.4 (95) 43.3 (33.6–53.9)
7 months to \5 years 40.3 (108) 35.4 (26.9–44.5)
5 years or more 24.3 (65) 21.3 (14.2–28.4)
Type of drug injected currently
White heroin 97.0 (261) 96.5 (93.2–99.0)
Other 3.0 (8) 3.5 (1.0–6.8)
Poly-drug, use in past 1 montha
Marijuana 66.5 (179) 64.5 (56.1–72.4)
Khat 10.8 (29) 14.8 (8.9–21.3)
Cocaine 3.7 (10) 5.7 (1.4–11.3)
Tranquilizers 58.0 (156) 50.1 (41.8–58.6)
Drug injection behaviors
Injection frequency in the past 1 month
Everyday 79.8 (214) 77.3 (70.6–84.8)
Less than everyday 20.2 (54) 22.7 (15.2–29.4)
Most common location where PWID inject
At base where drugs were boughtb 67.7 (182) 60.6 (52.3–67.5)
Home 34.6 (93) 24.9 (19.2–31.3)
Street or park 32.3 (87) 32.6 (25.5–39.9)
In dealer/peddler’s home 9.7 (26) 13.7 (8.6–19.3)
Any abandoned building 8.2 (22) 7.5 (3.8–11.3)
Injecting risk behaviors in the past 1 month
Receptive syringe sharingc 47.0 (126) 47.4 (38.8–55.9)
Used pre-filled needle/syringe 29.1 (78) 33.2 (25.4–41.3)
Front- or back-loaded needle/syringe 46.0 (123) 46.3 (38.1–55.0)
Shared water used to prepare drugs 59.0 (158) 57.1 (48.4–65.2)
Shared equipmentc 58.2 (156) 56.9 (48.7–64.6)
Drew drugs from common container 38.1 (102) 37.9 (29.7–46.7)
Lent needle/syringe 52.6 (141) 50.0 (41.6–57.9)
Risky Injection in the past 1 monthd 71.6 (192) 67.3 (58.9–75.6)
Lifetime injecting risk behaviors
Ever receptive syringe sharingc 56.1 (151) 53.8 (45.4–62.1)
Ever used pre-filled needle/syringe 39.9 (107) 41.8 (33.9–50.0)
Ever shared water used to prepare drugs 61.7 (166) 63.4 (55.4–70.6)
Ever shared equipmentd 65.1 (175) 64.4 (56.3–71.9)
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Having casual (5.4 %) and commercial (6.1 %) partners in
the past month was less common. Among female participants
only (n = 21), however, selling of sex was reported by 5 of
21 respondents (23.8 %, unadjusted, data not shown). Con-
sistent condom use with any partner was not common; only
20.8 % of sexually active PWID used condom consistently
in the most recent month. Nearly one-quarter (23.0 %) had
more than one partner in the prior 12 months. Over one-half
(63.7 %) of males who inject drugs indicated that their last
female sex partner has never injected drugs.
HIV Testing and HIV and STI Prevalence
A majority had previously tested for HIV (78.9 %). HIV
prevalence was 18.7 % (95 % CI 12.3–26.7). The preva-
lence of STI was lower than HIV prevalence [syphilis: 1.7 %
(95 % CI 0.2–6.0); gonorrhea: 1.5 % (95 % CI 0.1–4.9); and
Chlamydia: 4.2 % (95 % CI 1.2–7.8)]. Although the confi-
dence interval was wide and overlapped that of the males,
females who inject drugs had a much higher estimated HIV
prevalence (60.7 %; 95 % CI 14.7–87.2) compared to males
who inject drugs (15.4 %; 95 % CI 10.5–23.2). Approxi-
mately one-quarter (28.8 %) of those who tested HIV-posi-
tive were unaware that they were infected. Female PWID
were tested for Trichomoniasis and Bacterial vaginosis; of
the 21 women, 8 (38.1 %) were found positive for each of
these infections. (Data not shown)
Factors Associated with HIV Infection
Table 3 shows the bivariate and multivariable analyses of
the association between HIV-positive status and demo-
graphic and behavioral characteristics among PWID.
Bivariate analysis indicated that HIV-positive status was
significantly associated with being female (OR, 8.7;
p = 0.003) and longer time since first injection (OR, 4.6;
p = 0.001). Additionally, risky injecting practices in the
past 1 month (using a pre-filled needle or syringe, sharing
water used to prepare drugs, and drawing drugs from a
common container) as well as lifetime risky injection
practices (receptive syringe sharing, using a pre-filled
needle or syringe, sharing water used to prepare drugs, and
sharing equipment) were significantly associated with HIV-
positive status at the p \ 0.05 level.
In the final multivariable model (Table 3), HIV infection
was associated with being female (aOR, 3.5; p = 0.048),
having first injected drugs 5 or more years ago (aOR, 4.3;
p = 0.002), and ever having practiced receptive syringe
sharing (aOR, 6.2; p = 0.001). While Fig. 1 reflects only
peer recruitment, and not necessarily actual needle-sharing
relationships, it does show some clustering of PWID by HIV






Ever drew drugs from common container 51.3 (138) 48.6 (40.6–57.3)
Risky injection ever in lifetimee 78.8 (212) 80.0 (73.9–85.5)
Sexual behaviors
Sexually active in the past 1 month 39.0 (105) 40.7 (32.3–49.5)
Partner type in the past 1 month
No partner 60.6 (163) 59.0 (50.4–67.2)
Regularf 28.3 (76) 29.5 (21.7–38.0)
Casualf 4.8 (13) 5.4 (1.4–10.8)
Commercialf 6.3 (17) 6.1 (2.8–10.1)
Condom use in the past 1 month among sexually active PWID (n = 105)
Always 17.1 (18) 20.8 (8.5–36.1)
Sometimes/never 82.9 (87) 79.2 (63.9–91.5)
Multiple sex partners in past 12 months
None or 1 partner 76.2 (205) 77.0 (68.6–83.8)
More than one partner 23.8 (64) 23.0 (16.2–31.4)
Last female sex partner ever injected drugs (among sexually active male
PWID) (n = 86)
Yes 36.1 (31) 36.3 (26.6–69.2)
No 63.9 (55) 63.7 (30.8–73.4)
Knows HIV status (from prior testing)
Yes 80.0 (212) 78.9 (72.7–85.8)
No 20.0 (53) 21.1 (14.2–27.3)
HIV prevalence (All) 21.2 (57) 18.7 (12.3–26.7)
Gender
Male 19.4 (48) 15.4 (10.5–23.2)
Female 42.9 (9) 60.7 (14.7–87.2)
Age
B34 years 26.7 (46) 22.1 (13.3–33.2)
35 years or older 11.3 (11) 13.0 (4.8–23.3)
STI prevalence
Syphilis 1.5 (4) 1.7 (0.2–6.0)
Gonorrhea 1.1 (3) 1.5 (0.1–4.9)
Chlamydia 3.4 (9) 4.2 (1.2–7.8)
a Concurrent drug use (injected or non-injected) with at least one
other drug injected in the past 1 month
b A base is typically a public open outdoor space where PWID buy
drugs. PWID may inject there as well
c Receptive syringe sharing refers to using a needle/syringe used by
someone else
d Sharing equipment includes sharing of dropper, water, bleach, and
other cleaning agents
e Risky injection practices variable is a composite variable that
includes using needles/syringe after someone else used, using a pre-
filled needle/syringe, front- or back-loading injections, sharing of
preparation water, sharing of other injections equipment, or drawing
drugs from a common container
f Regular partner: Someone with whom the respondent had an
ongoing or long-term intimate sexual relationship; it included live-in
partners and spouses. Casual partner: A partner with whom the
respondent did not have an ongoing or intimate sexual relationship,
and includes one-time encounters. Commercial partner: A partner
who the respondent paid for sex or paid the respondent for sex with
money, goods or services
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engaged in receptive syringe sharing). Specifically, 23 HIV-
positive respondents who have ever engaged in receptive
syringe sharing were recruited into the study by a participant
with the same characteristics (HIV-positive, ever engaged in
receptive sharing) and only 5 HIV-positive respondents were
recruited into the study by a participant with a different
receptive syringe sharing profile.
Discussion
This study is the first to report population-based preva-
lence of HIV, STIs, and risk behaviors in PWID in
Nairobi, Kenya. Our findings indicate high seroprevalence
of HIV and high levels of risky injection behaviors.
Moreover, we found that HIV infection was indepen-
dently associated with lifetime practice of using previ-
ously used needles and syringes and longer time since
first injection.
Our findings of 18.7 % (95 % CI 12.3–26.7) HIV
prevalence is similar to that found in Zanzibar (16.1 %;
95 % CI 11.3–21.1), which also used RDS [44]. However,
our HIV prevalence is slightly lower than that reported in a
previous study of PWID in Nairobi, which found HIV
prevalence of 36.3 % [45], as well as those reported in
Table 3 RDS-weighted bivariate and multivariate associations between demographic and selected variables and HIV infection among PWID,
Nairobi, 2011 (N = 269)
Variable OR p value aORa 95 % CI p value
Demographic characteristics
Age
B34 years 1 1
35 years or older 0.5 0.117 0.4 0.1–1.1 0.072
Gender
Male 1 1
Female 8.7 0.003 3.5 1.0–12.2 0.048
Education
Primary or less 1
Secondary or higher 1.1 0.790
Injection behaviors (lifetime)
Time since first injection
0–4 years 1 1
5 years or more 4.6 0.001 4.3 1.7–10.9 0.002
Risky injection ever in lifetimeb 3.8 0.050
Receptive syringe sharingc 7.9 \0.0001 6.2 2.2–17.6 0.001
Used pre-filled needle/syringe 5.1 \0.0001
Front- or back-loaded needle/syringe
Shared water used to prepare drugs 3.6 0.014
Shared equipmentd 3.9 0.006
Drew drugs from common container 1.8 0.203
Injection behaviors (past 1 month)
Risky injection in the past 1 monthb 2.0 0.127
Receptive syringe sharingc 2.2 0.063
Used pre-filled needle/syringe 2.5 0.033
Front- or back-loaded needle/syringe 2.3 0.052
Shared water used to prepare drugs 2.6 0.025
Shared equipmentd 2.1 0.101
Drew drugs from common container 3.1 0.008
a Adjusted for all other variables in the model
b Risky injection practices include using needles/syringe after someone else used, using a pre-filled needle/syringe, front- or back-loading
injections, sharing of preparation water, sharing of other injections equipment such as spoons or cookers, or drawing drugs from a common
container
c Receptive syringe sharing refers to using a needle/syringe used by someone else
d Sharing equipment includes sharing of dropper, water, bleach, and other cleaning agents
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other east African countries: 47 % in Mauritius, 27–58 %
in Tanzania, and 26 % in Zanzibar [15, 46–48]. However,
these studies were not based on a probability-based sample
with the exception of Mauritius. Another recent study of
PWID in Nairobi was implemented using RDS methods
shortly after this study, and reported an equivalent HIV
prevalence of 18.3 % [21]. Thus the similarity in HIV
prevalence estimates from these two studies illustrates the
reliability of the RDS method when conducted from dif-
ferent central locations in the Nairobi area.
The HIV prevalence among male PWID (15.4 %) in
Nairobi is 3.5 times as high as that of men aged
15–49 years (4.4 %) in the general population [17].
Immediate comprehensive prevention programming,
including harm-reduction interventions, is warranted in
order to prevent transmission of HIV among PWID and to
their non-injecting sex partners. In fact, our data indicated
that over one-half of males who inject drugs in Nairobi
who were sexually active had non-injecting female part-
ners. Thus, this bridge from PWID to the non-injecting
population has a very high potential for fueling the pan-
demic in the general, non-injecting population. Therefore,
by not fully addressing HIV infection in key populations
with high HIV prevalence, such as in PWID, current efforts
to reduce HIV spread in the general population could be
compromised.
The small number of female PWID in this survey is
similar to other studies conducted in African settings [16,
49–51]. Although the estimate may be imprecise due to the
small sample size, there is indication that the HIV preva-
lence among women may be higher than that of the men
(60.7 vs. 15.4 %). Other African studies have documented
HIV prevalence to be 2–10 times as high among female as
among male PWID [16, 47, 52–54]. Furthermore, in our
final multivariable model, being female was borderline
significantly associated with HIV infection. Additional
research is needed to estimate the population size of female
PWID in Nairobi and to better understand risk behaviors
and access to prevention services in this sup-population to
inform prevention programs targeting PWID that may
include women.
Based on our estimated HIV prevalence of 18.7 % and
the estimated PWID population size range of 6,216–10,937
in Nairobi [19], there are an estimated 1,162–2,045 HIV-
positive PWID in Nairobi. One-quarter of those testing
HIV-positive did not know they were infected; thus, there
is need to increase HIV testing rates among PWID. HIV-
positive PWID will also need to be linked to HIV care and
treatment services. HIV treatment can serve as prevention
when combined with other HIV prevention efforts [55].
Therefore, programs should ensure that PWID are not
denied HIV treatment due to stigma and discrimination
against PWID.
Furthermore, in the multivariable model of factors
associated with HIV infection, longer time since first
injection (5 years or longer) was a strong independent
factor, which represents increased risk of infection rela-
ted to the cumulative exposure to injection-related risk
over time. This is similar to other studies which found
higher HIV prevalence among longer term PWID [56,
57]. We also found that a high proportion (43 %) of
PWID in Nairobi initiated drug injection within the past
6 months, nearly 80 % initiated in the past 5 years, and
many are daily injectors. Prospective studies, conducted
at the height of the HIV epidemics in other countries,
found higher HIV incidence among recent-onset PWID
[30, 57–59]. As such, evidence-based prevention pro-
grams tailored toward PWID would benefit from target-
ing this population soon after injection initiation to
establish safer injection practices early and to stop drug
use while the habit is still new. Substance abuse coun-
seling and treatment, including medication assisted
treatment, should be available to all PWID to support
reduction and eventual cessation in drug injection. Pro-
grams targeted at recently-initiated PWID should also
consider that many of them are daily injectors. It is not
uncommon for recently-initiated PWID to inject daily.
Nearly all PWID in our study injected heroin, which is
highly addictive and typically requires daily use to pre-
vent withdrawal. Based on our formative assessment,
heroin in Nairobi is high in purity which makes it pos-
sible to snort. It is possible that PWID in our study
began using heroin through snorting and thus may have
already been addicted to heroin and likely using daily
when they transitioned to injecting.
Similar to other studies conducted in sub-Saharan Africa
[24–27], PWID in Nairobi reported high levels of both
lifetime and past-month risky injection behaviors, includ-
ing receptive syringe sharing, front- or back-loading nee-
dle/syringes, and sharing water used to prepare drugs.
Furthermore, ever receptive syringe sharing remained
independently associated with HIV infection. Equally
alarming is the high proportion of PWID in Nairobi lending
their needles/syringes to others; of those who did so, nearly
one-quarter were HIV-positive. Together these findings
highlight the urgent need to strengthen current outreach
efforts to increase personal awareness of risk and to
decrease sharing of injection equipment. Such efforts
should be coupled with increased access to sterile injection
equipment. Needle and syringe programs, as part of a
comprehensive prevention approach for PWID, have been
found to be an effective and cost-effective approach to
reducing injection-related risk behaviors and the spread of
HIV, without negative consequences [60, 61], and may be
an important venue to reach HIV-positive PWID for link-
age to HIV care and treatment.
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Poly-drug use, particularly heroin in conjunction with
tranquilizers, was found to be common among PWID in
Nairobi. Poly-drug use can be fatal, especially if heroin is
used in combination with benzodiazepines (tranquilizers)
[62, 63]. Such combination also has implications for drug
abuse treatment as methadone treatment may not be as
effective for heroin users if the tranquilizer use is also not
addressed [62–64]. If medically assisted therapy is to be
initiated in Kenya, guidelines will be needed to address
issues related to treating poly-drug use. Additionally,
studies have found that opiate users who also used ben-
zodiazepines were more likely to have psychological vul-
nerabilities (i.e., depression, self-harm attempts) [63, 65,
66]. Prevention and treatment programs need to address
these psychological co-morbidities.
Nairobi PWID indicated that they injected drugs where
they bought the drugs or on the street, which suggests that
outreach should be used to target prevention activities in
these areas. PWID typically congregate at these ‘bases’,
which are typically outdoor public areas where drug
dealers sell drugs and are well-known by PWID. Even
PWID who want to remain anonymous come to the bases
to buy drugs; however, they typically stay in their cars
and do not linger to inject at the base. Thus, outreach to
these ‘hotspots’ can be ideal for reaching a variety of
PWID with prevention activities. Outreach is one of the
most commonly used and more effective strategies for
reaching PWID with harm reduction interventions [67–
70].
Sexual activity was fairly low among PWID; only four
out of ten PWID reported being sexually active in the past
1 month. Few PWID engaged in casual and commercial
sexual activity. Most of the sexually active PWID had
regular partners. However, the majority did not use con-
doms consistently in these sexual partnerships, thus putting
PWID and their regular partners at risk for HIV and other
STIs. These findings are suggestive that risky injecting
behaviors rather than sexual practices may be the most
important factor contributing to HIV transmission among
this population. Although drug-injecting behaviors should
remain the focus of any harm-reduction programs, condom
use, particularly within regular partnerships, should be part
of a comprehensive HIV prevention program for PWID.
Some limitations should be mentioned. The actual
sample size was lower than our target sample size due to
the time and resources available. Low recruitment may
have been due in part to the distance of the study site
from drug-using locations. Recruitment remained low
despite attempts to offer transport to the study site from
drug-using locations. Although the relatively small sample
size resulted in wider CI for some estimates, particularly
HIV prevalence in female PWID, the estimates still pro-
vide useful information for programs and policies as this
was a rigorously conducted population-based study. While
it is possible that fewer females participated in the study
due to the study’s STI testing procedures such as a vag-
inal swab, it is likely to be minimal since they were free
to decline this procedure. The study’s small proportion of
females is also in line with other studies of PWID in the
African region. Further research is needed particularly for
female PWID. Future studies with PWID should also
make an effort to recruit middle- and upper-class PWID.
Additionally, the high proportion of recently initiated
PWID may be a result of sampling bias that RDS is not
able to account for or social desirability bias (if partici-
pants perceive longer term use as negative). However,
high proportions of recently initiated PWID have been
observed in other surveillance surveys with PWID. In
Nigeria, the median time since first injection was
2–7 years across six states [16]. Lastly, assumptions for
RDS must be met in order to arrive at an unbiased esti-
mate. Based on our formative assessment for this survey,
two of the four assumptions were likely met (i.e., the
target population know each other as members of the
population in question and networks form one single large
component). The assumption that participants report net-
work size accurately was likely met given that the mean
(26), median (10), and the interquartile range (5 and 20)
are reasonable. The last assumption (i.e., random
recruitment of peers) is difficult to assess within the
context of a surveillance survey.
Conclusion
Our findings indicate that given the high HIV prevalence
and the high levels of risky injection practices among
PWID in Nairobi, there is a potential to see increases in
HIV prevalence in this population. In addition, more than
one-half of sexually active PWID had non-injecting sex
partners, thus HIV infection among PWID may continue to
fuel the HIV epidemic in the general, non-injecting popu-
lation. Thus, comprehensive, harm-reduction programs
tailored toward PWID and their sex partners need to be
implemented in full force. Comprehensive harm reduction
programs for PWID include access to sterile injection
equipment, drug dependence treatment, ART for those who
are HIV positive, HIV counseling and testing, prevention
and treatment of STIs, prevention, vaccination, and treat-
ment of viral hepatitis, prevention and treatment of TB, and
risk reduction information for PWID and their sex partners,
and condom distribution for PWID and their sex partners
[71]. There is evidence of harm-reduction programs
reducing risky injection behaviors, and countries that have
implemented harm-reduction programs have seen declines
in new drug-related HIV infections [72, 73]. Modeling
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exercises show that if key interventions such as HIV
counseling and testing, needle exchange and drug treatment
such as medication-assisted treatment are offered along
with needed expansion of ART, approximately 2,000 new
HIV infections could be averted among PWID between
2012 and 2015 throughout Kenya, which represents a 56 %
reduction compared to the status quo scenario [4]. There is
evidence that PWID can adhere to ART regimen with
supportive interventions such as psychosocial support,
medication assisted therapy for drug dependence, directly
administered ART, and nurse-delivered interventions
[74–76].
The Kenyan NASCOP, Kenya AIDs and NGOs Con-
sortium through the support of AIDS Alliance (KANCO),
and the Kenya Red Cross through Global Fund are initi-
ating harm-reduction interventions per the WHO and
Kenya’s guidelines including needle and syringe exchange
programs, medication assisted therapy with both powdered
and liquid methadone, Hepatitis C screening, Hepatitis B
screening and vaccination, and opiate overdose manage-
ment with Naloxone in Nairobi, Mombasa, and Kilifi
counties [4, 77]. The program has also included the pro-
vision of two different sizes of needles (23G/1 ml and 28G/
3 ml) as some prefer smaller gauge needles in order to
reduce the scars on their body [77]. The harm reduction
program is also currently working with the law enforce-
ment sector to sensitize them on the issues related to PWID
and harm reduction. Research and evaluations are needed
to determine the effectiveness of these programs in
reducing the impact of HIV in this key population as well
as the general population and document lessons learned
from the implementation. Integrated bio-behavioral sur-
veillance (BBS) should continue in order to monitor sexual
and injecting behaviors among PWID, their access to
prevention and harm reduction programs, and effect of
these programs on trends in HIV prevalence in this popu-
lation. The BBS should also be expanded to other areas in
Kenya with drug injection problem, particularly in the
coastal areas.
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